Transcell’s Transtoxbio vertical was created to offer human surrogate cell/tissue in vitro systems to meet the need of investigation adopting next generation and alternative approaches in preclinical, clinical testings. We are dedicated to supporting innovative in vitro science and applications through our offerings to global markets. We have unique expertise in the field of primary, progenitor cell/tissue based platform production, supply, and the specialty in vitro testing services to guide the users’ preclinical exploratory research requirement spanning the drug, vaccine, and cosmetics industry. We come from the school of belief that the right kind of testing platforms decide the test material’s fate with its actual application, function revealed while on a mission to offer the best, tried and tested in vitro solutions to the research requirement.


Since 2016, our team has succeeded in understanding the needs of the industry and creating reliable products to serve them all

Our products are invitro alternatives to animal models and testings with eligibility to be recognized by OCED ( Organization for Economic Cooperation and Development), ICCVAM ( Interagency Coordinating committee on the validation of alternative methods), ECVAM ( European center for the validation of alternative methods).

Learn more about our products –

Learn more


Transtoxbio has all primary human sourced progenitor cell based platforms for invitro exploratory testing of

  •        Chemical libraries
  •        Hit compounds
  •        Lead candidates
  •        Investigational New drug candidates
  •        Known drugs for repurposing, repositioning
  •        Cosmetics
  •        Biomaterials

We also support customers in their projects for different sectors such as Pharmaceuticals, Drug discovery, Cosmeceuticals, Natural products, Agrochemicals, 3D bioprinting, Exosomes production and Implants (Biomaterials).

  •       Supporting standard and customized invitro testings for high  throughput screening.
  •       Compounds selection, lead optimization, pre-regulatory toxicity and related next generation testings contributing to 3Rs (Replacement, Reduction, Refinement) and animal welfare.

Transtoxbio platforms have the power to read the following reproducible, predictive standard invitro measurable test end points relevant to human physiology such as;

  •     Embryotoxicity, Genotoxicity, Metabolomics, Transcriptomics, Proteomics, Toxicogenomics, Stem cell cytotoxicity, IC50 on human primary stem cells, Stem cell permeability, Cell distribution, Neurotoxicity, Neurogenesis, Neuroprotective properties, Hepatotoxicity and Tumorogenesis.
  •     Transdifferentiating Abilities and Spheroid Formation  Assays
  •     Implants toxicity
  •     Colony Forming Units Assay and Hematopoiesis
  •     Humanizing 3D prints and Humanizing mouse models

Number of Views : 301 total views,  3 views today

Back to Top